Leerink Partnrs Brokers Lift Earnings Estimates for IRWD

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Analysts at Leerink Partnrs boosted their Q3 2025 earnings per share (EPS) estimates for shares of Ironwood Pharmaceuticals in a research note issued to investors on Monday, April 14th. Leerink Partnrs analyst F. Khurshid now forecasts that the biotechnology company will post earnings per share of $0.12 for the quarter, up from their previous forecast of $0.07. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share.

Several other research analysts have also recently commented on the company. Craig Hallum cut Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 16th. JMP Securities lowered their price objective on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating on the stock in a research report on Thursday, January 30th. Citizens Jmp lowered Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Monday, April 14th. Jefferies Financial Group reissued a "hold" rating and issued a $0.70 price objective (down from $8.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Finally, Leerink Partners decreased their price target on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating on the stock in a report on Monday, April 14th. Eight equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $4.78.

Ironwood Pharmaceuticals Stock Performance

NASDAQ IRWD traded down $0.01 during trading hours on Wednesday, reaching $0.72. 700,955 shares of the company's stock were exchanged, compared to its average volume of 2,556,258. The company has a market capitalization of $116.50 million, a price-to-earnings ratio of -24.00 and a beta of 0.30. Ironwood Pharmaceuticals has a one year low of $0.59 and a one year high of $8.45. The company's 50-day moving average is $1.44 and its two-hundred day moving average is $3.00.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.08). The firm had revenue of $90.55 million during the quarter, compared to the consensus estimate of $93.85 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in IRWD. Pacer Advisors Inc. increased its position in shares of Ironwood Pharmaceuticals by 4.0% during the 4th quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company's stock valued at $51,967,000 after purchasing an additional 450,949 shares during the last quarter. State Street Corp grew its stake in Ironwood Pharmaceuticals by 7.3% during the third quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company's stock valued at $40,870,000 after acquiring an additional 677,024 shares in the last quarter. FMR LLC increased its holdings in shares of Ironwood Pharmaceuticals by 25.1% in the third quarter. FMR LLC now owns 169,681 shares of the biotechnology company's stock worth $699,000 after purchasing an additional 34,089 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of Ironwood Pharmaceuticals by 102.7% in the third quarter. Jane Street Group LLC now owns 323,638 shares of the biotechnology company's stock valued at $1,333,000 after purchasing an additional 164,006 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Ironwood Pharmaceuticals by 4.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,983,240 shares of the biotechnology company's stock valued at $8,786,000 after acquiring an additional 78,969 shares during the last quarter.

Insider Activity

In other news, CMO Michael Shetzline sold 41,269 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $72,633.44. Following the transaction, the chief marketing officer now owns 554,007 shares in the company, valued at approximately $975,052.32. This trade represents a 6.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Thomas A. Mccourt sold 139,064 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the completion of the sale, the chief executive officer now owns 1,160,634 shares in the company, valued at approximately $2,042,715.84. This represents a 10.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 192,381 shares of company stock worth $338,591 in the last three months. Corporate insiders own 12.90% of the company's stock.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.